anti-EpCAM/anti-CD3 bispecific antibody A-337

A T-cell engager (TCE) and bispecific antibody composed of two fragments targeting the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326) and one targeting the T-cell surface glycoprotein CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-EpCAM/anti-CD3 bispecific antibody A-337 targets and binds to EpCAM on EpCAM-expressing tumor cells and CD3 on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to EpCAM-expressing tumor cells, which results in the CTL-mediated cell death of EpCAM-expressing tumor cells. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.